Skip to content
← Full study record

NCT04099277 · MORE INFO

Limitations, agreements, and source contact

A Study of LY3435151 in Participants With Solid Tumors · Source last updated 2021-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
This study was terminated before completion of the dose escalation phase (Part A), due to strategic business decision made by the company.
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
This study was terminated before completion of the dose escalation phase (Part A), due to strategic business decision made by the company.
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice